Jazz Pharmaceuticals JAZZ Oncology — Revenue from Contract with Customer, Excluding Assessed Tax

Other product segments

Similar metrics at other companies

ETROther revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$36.28M-41.5%

KMXService revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$24.2M+24.1%

TNLAncillary Revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$0-100%

TNLTransaction Revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$109M-6.8%

QSRProperty revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$0-100%

NTRSOther — Revenue from Contract with Customer, Excluding Assessed Tax

$68.6M+8.2%

FAQ

What is Jazz Pharmaceuticals's oncology — revenue from contract with customer, excluding assessed tax?

Jazz Pharmaceuticals (JAZZ) reported oncology — revenue from contract with customer, excluding assessed tax of $333.4M in Q1 2026.

How has Jazz Pharmaceuticals's oncology — revenue from contract with customer, excluding assessed tax changed year-over-year?

Jazz Pharmaceuticals's oncology — revenue from contract with customer, excluding assessed tax increased by 45.3% year-over-year, from $229.4M to $333.4M.

What is the long-term trend for Jazz Pharmaceuticals's oncology — revenue from contract with customer, excluding assessed tax?

Over 2 years (2021 to 2023), Jazz Pharmaceuticals's oncology — revenue from contract with customer, excluding assessed tax has grown at a 17.6% compound annual growth rate (CAGR), from $733.81M to $1.02B.

What does oncology — revenue from contract with customer, excluding assessed tax mean?

This metric represents the total net revenue generated from the sale of pharmaceutical products within the oncology therapeutic area, excluding any taxes assessed on the transaction. It reflects the commercial performance and market adoption of the company's cancer treatment portfolio, including chemotherapy and targeted therapy agents. This figure is a critical indicator of the company's ability to monetize its oncology pipeline and maintain competitive positioning in the specialized cancer care market.